Information Provided By: 
Fly News Breaks for May 25, 2018
TEVA, AMRN
May 25, 2018 | 07:25 EDT
Cantor Fitzgerald analyst Louise Chen believes the terms of the settlement agreement with Teva (TEVA) resolving Vascepa patent litigation are favorable to Amarin (AMRN). Under the settlement, Teva will not begin selling generic Vascepa in the U.S. until August 9, 2029, which is just six months off the expiry date of Vascepa's patents, Chen tells investors in a research note. She keeps an Overweight rating on Amarin with a $10 price target.
News For AMRN;TEVA From the Last 2 Days
There are no results for your query AMRN;TEVA
